DEA Temporarily Bans New Tramadol Variant
Published Date: 6/24/2026
Rule
Summary
Starting July 24, 2026, O-desmethyltramadol (also called O-DSMT) will be temporarily placed in Schedule I, meaning it’s treated like the most tightly controlled drugs. This affects anyone who makes, sells, studies, or even just possesses it, bringing strict rules and penalties. The move aims to keep people safe while the government studies the drug more closely.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Legal Controls and Penalties for Handlers
Once the temporary order is published, anyone who manufactures, distributes, reverse distributes, imports, exports, researches, conducts instructional activities or chemical analysis with, or possesses O-DSMT will be subject to the regulatory controls and the administrative, civil, and criminal sanctions that apply to Schedule I substances. Those sanctions apply immediately upon the order's publication and last for the duration of the temporary scheduling (two years from publication, with a possible one-year extension).
O-DSMT Temporarily Placed in Schedule I
O-Desmethyltramadol (O-DSMT) will be temporarily listed in Schedule I when DEA publishes the temporary order in the Federal Register (the order will not be issued before July 24, 2026). The temporary listing will remain in effect for two years from publication and can be extended for one additional year if formal scheduling proceedings are initiated.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-15624, Amendment to 3,4-MDP-2-P Methyl Glycidic Acid, a List I Chemical
The Drug Enforcement Administration is proposing to modify the listing of the list I chemical 3,4-MDP-2-P methyl glycidic acid (also known as PMK glycidic acid) to include esters of 3,4-MDP-2-P methyl glycidic acid, not listed elsewhere in the Controlled Substances Act (CSA), as list I chemicals under the CSA. The current listing of 3,4- MDP-2-P methyl glycidic acid includes its salts, optical and geometric isomers, and salts of isomers. DEA proposes the new listing to read as follows: 3,4-MDP-2-P methyl glycidic acid (PMK glycidic acid) and its esters, not listed elsewhere in the CSA, its optical and geometric isomers, its salts, salts of its optical and geometric isomers, salts of its esters, not listed elsewhere in the CSA, and any combination thereof, whenever the existence of such is possible.
2026-15328, Joan Rubinger, N.P.; Decision and Order
2026-15199, Kerri Zavota, DVM; Decision and Order
2026-15201, Gene M. Koop, D.D.S.; Decision and Order
Previous / Next Documents
Previous: 2026-12653, Schedules of Controlled Substances: Placement of Bromazolam in Schedule I; Correction
The DEA fixed a typo in the official chemical name of bromazolam, a drug they put in the strictest Schedule I category starting March 16, 2026. This correction makes the rules clear for everyone involved, especially law enforcement and drug handlers. No new fees or deadlines, just a clean-up to keep things accurate and official.
Next: 2026-12669, Indefinite Suspension of the De Minimis Exemption for Mail Shipments and New Postal Informal Entry Process
Starting July 24, 2026, the U.S. Customs and Border Protection is stopping the $800 tax-free rule for mail shipments coming into the U.S. Instead, a new process will handle these packages to better track and tax imports. This change affects anyone sending or receiving international mail and aims to protect U.S. revenue from unpaid duties.